MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 21.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 79,967 shares of the company’s stock after buying an additional 14,125 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.09% of CRISPR Therapeutics worth $3,143,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Arkadios Wealth Advisors grew its position in shares of CRISPR Therapeutics by 7.7% during the 4th quarter. Arkadios Wealth Advisors now owns 12,161 shares of the company’s stock valued at $479,000 after acquiring an additional 866 shares during the period. MCF Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $80,000. Hedges Asset Management LLC grew its position in shares of CRISPR Therapeutics by 5.1% during the 4th quarter. Hedges Asset Management LLC now owns 24,350 shares of the company’s stock valued at $958,000 after acquiring an additional 1,188 shares during the period. PFG Investments LLC boosted its holdings in CRISPR Therapeutics by 9.9% in the 4th quarter. PFG Investments LLC now owns 10,603 shares of the company’s stock worth $417,000 after buying an additional 952 shares during the period. Finally, KBC Group NV boosted its holdings in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after buying an additional 57,696 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $38.68 on Tuesday. The company has a market capitalization of $3.34 billion, a P/E ratio of -8.85 and a beta of 1.88. The company’s 50-day simple moving average is $37.40 and its two-hundred day simple moving average is $42.24. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business’s quarterly revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.43) earnings per share. On average, research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, Director John Greene acquired 7,000 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRSP has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price target for the company from $60.00 to $99.00 in a report on Friday, February 14th. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.